Moderna’s COVID-19 vaccine demonstrates 94.5% efficacy


Just 1 week after Pfizer and BioNTech’s early Phase III trial data were released, more good news comes from Moderna’s COVID-19 vaccine Phase III interim results.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment